Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,065
Total Claims
$6.0M
Drug Cost
1,066
Beneficiaries
$5,593
Cost/Patient
Risk Score Breakdown 13/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+296%
Cost per patient vs peers
$5,593 vs $1,411 avg
+441%
Brand preference vs peers
57.5% vs 10.6% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
Brand vs Generic
Brand: 5,391 claims · $5.8M
Generic: 3,985 claims · $79K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 603 | $885K |
| Empagliflozin | 694 | $752K |
| Semaglutide | 367 | $499K |
| Insulin Aspart | 294 | $415K |
| Insulin Lispro | 244 | $326K |
| Insulin Glargine,hum.Rec.Anlog | 306 | $280K |
| Dapagliflozin Propanediol | 242 | $252K |
| Semaglutide | 109 | $181K |
| Tirzepatide | 125 | $176K |
| Insulin Lispro | 90 | $165K |
| Insulin Glargine,hum.Rec.Anlog | 191 | $154K |
| Insulin Detemir | 142 | $154K |
| Insulin Glargine/Lixisenatide | 129 | $142K |
| Insulin Aspart | 71 | $114K |
| Liraglutide | 41 | $112K |
Prescribing Profile
Patient Profile
70
Avg Age
63%
Female
1.50
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data